Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ApTOLL for Acute Ischemic Stroke (APRIL)
NCT04734548Phase 2Completed
- Sponsor
- aptaTargets
- Start
- Oct 2020
- Primary completion
- Jul 2022
- Modality
- Antisense DNA, RNA Aptamers, Small Interfering RNA (siRNA)
- Countries
- 3
01
Overview
A Phase 2 trial of aptoll in acute ischemic stroke (AIS), sponsored by aptaTargets. Started Oct 2020; status: completed.
02
Drugs
aptoll
03
Conditions
acute ischemic stroke (AIS)
Beyond the preview
Go deeper on NCT04734548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04734548.